ACXP
Acurx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ACXP
Acurx Pharmaceuticals, Inc.
A clinical stage biopharmaceutical company that developing a new class of antibiotics for difficult-to-treat bacterial infections
259 Liberty Avenue, Staten Island, NY 10305
--
Acurx Pharmaceuticals, Inc., incorporated in Delaware in July 2017, began operations in February 2018. The Company is a late-stage biopharmaceutical company focused on the development of novel small molecule antibiotics for refractory bacterial infections for the treatment of infections caused by bacteria classified as priority pathogens by the World Health Organization (" WHO "), the U.S. Centers for Disease Control and Prevention (" CDC ") and the U.S. Food and Drug Administration (" FDA "). Priority pathogens are those that require new antibiotics to address the global antimicrobial resistance (" AMR ") crisis identified by the WHO, CDC and FDA.
Earnings Call
Q1/2025
Estimate EPS-0.14
Actual EPS-0.11
Estimate Revenue--
Actual Revenue0
Acurx Pharmaceuticals' 2025 Q1 Earnings Call: Unpacking Contradictions in Funding, Phase 3 Trials, and Strategic Partnerships
May 20,2025 10:51
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.1
Actual EPS-1.89
Estimate Revenue--
Actual Revenue0
Acurx Pharmaceuticals Q2 2025: Key Contradictions in Funding, Phase III Trials, and Strategic Partnerships
Aug 12,2025 10:36
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-1.49
Actual EPS-1.23
Estimate Revenue--
Actual Revenue0
Acurx's Q3 2025 Earnings Call: Contradictions in Partnership Timelines, Operating Expenses, and Phase III Trial Plans
Nov 12,2025 10:39
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ACXP has released its 2025 Q3 earnings. EPS was reported at -1.23, versus the expected -1.49, beating expectations. The chart below visualizes how ACXP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
